EUVIMEDEUVIMED entdecken
MetaanalyseÜbersichtsarbeit

Efficacy and Safety of Olezarsen in Hypertriglyceridemia: An Updated Meta‐Analysis of Randomised Controlled Trials

Ahmed Emara iD, Ahmed Mansour, Heba Aboeldahab, Ameer Awashra, Omar F Abbas, Hamza A Abdul-Hafez, Amal A Alsubaiei, Najat AlSejari, Hamad Salman Saif, Abdalhakim Shubietah, Mohammed Mhanna

Diabetes, Obesity and Metabolism · 2026

DOI: 10.1111/dom.70716 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Ahmed Emara und 10 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Al-Azhar University, Cairo, Egypt. Hauptthemen laut MEDLINE: Hypertriglyceridemia, Oligonucleotides. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Hypertriglyceridemia is a common lipid disorder linked to residual cardiovascular risk and acute pancreatitis despite standard therapy. Olezarsen, an antisense oligonucleotide targeting apolipoprotein C‐III (ApoC‐III), offers a novel triglyceride‐lowering strategy. We performed an updated meta‐analysis to evaluate its efficacy and safety. Methods and Materials We performed a meta‐analysis of randomised controlled trials (RCTs) identified through PubMed, Cochrane, Scopus and Web of Science up to December 2025. Random‐effects models were used to pool mean percentage changes (MDs) and risk ratios (RRs) with 95% confidence intervals (CIs). PROSPERO ID: CRD420261279110.

Results

Six RCTs with 2676 participants were analysed. Olezarsen significantly reduced triglycerides at 50 mg (MD −46.61%, 95% CI −49.59 to −43.64) and 80 mg (MD −54.37%, 95% CI −61.26 to −47.48), both p < 0.0001. ApoC‐III was markedly reduced (50 mg: MD −63.51%, 95% CI −74.18 to −52.84; 80 mg: MD −66.88%, 95% CI −77.91 to −55.85; both p < 0.0001). Non‐HDL‐C also decreased significantly (50 mg: MD −21.41%, 95% CI −25.12 to −17.70; p < 0.0001; 80 mg: MD −25.28%, 95% CI −33.99 to −16.58; p = 0.001). LDL‐C increased modestly at 50 mg (MD 17.58%, 95% CI 0.24 to 34.93; p = 0.047). Olezarsen reduced acute pancreatitis risk (50 mg: RR 0.16, 95% CI 0.05–0.48; p = 0.001; 80 mg: RR 0.33, 95% CI 0.14–0.76; p = 0.009). Overall adverse events were comparable to placebo, while ALT/AST ≥ 3 × ULN increased with 80 mg (RR 2.56, 95% CI 1.20–5.44; p = 0.01).

Conclusions

Olezarsen provides substantial triglyceride reduction with favourable effects on atherogenic lipoproteins and a tolerable short‐term safety profile. Longer‐term trials are needed to confirm cardiovascular outcomes and safety.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypertriglyceridemiaOligonucleotidesHumansRandomized Controlled Trials as TopicApolipoprotein C-IIITriglyceridesTreatment OutcomePancreatitis

Stichwörter der Autor:innen

apolipoprotein C‐IIIhypertriglyceridemiameta‐analysisolezarsenpancreatitisrandomised controlled trials

Substanzen

Apolipoprotein C-IIIOligonucleotidesTriglyceridesISIS 304801olezarsen

Autor:innen und Institutionen

  • Faculty of Medicine, Al-Azhar University, Cairo, Egypt.
  • Clinical Research Department, El-Gomhoria General Hospital, MOHP, Alexandria, Egypt.
  • Department of Medicine, An-Najah National University, Nablus, West Bank, Palestine.
  • Kuwait Institute for Medical Specializations, Kuwait City, Kuwait.
  • Department of Internal Medicine, King Hamad University Hospital, Busaiteen, Bahrain.
  • Department of Medicine, Advocate Illinois Masonic Medical Center, Chicago, Illinois, USA.

ORCID-Profile: Ahmed Emara

Zitieren

APA

Emara, A., Mansour, A., Aboeldahab, H., Awashra, A., Abbas, O. F., Abdul-Hafez, H. A., Alsubaiei, A. A., AlSejari, N., Salman Saif, H., Shubietah, A., & Mhanna, M. (2026). Efficacy and Safety of Olezarsen in Hypertriglyceridemia: An Updated Meta‐Analysis of Randomised Controlled Trials. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70716

Vancouver

Emara A, Mansour A, Aboeldahab H, Awashra A, Abbas OF, Abdul-Hafez HA, et al. Efficacy and Safety of Olezarsen in Hypertriglyceridemia: An Updated Meta‐Analysis of Randomised Controlled Trials. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70716

BibTeX
@article{Emara2026,
  author = {Emara, Ahmed and Mansour, Ahmed and Aboeldahab, Heba and Awashra, Ameer and Abbas, Omar F and Abdul-Hafez, Hamza A and Alsubaiei, Amal A and AlSejari, Najat and Salman Saif, Hamad and Shubietah, Abdalhakim and Mhanna, Mohammed},
  title = {Efficacy and Safety of Olezarsen in Hypertriglyceridemia: An Updated Meta‐Analysis of Randomised Controlled Trials},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  doi = {10.1111/dom.70716}
}
Kostenlos starten →